CorMedix (CRMD) COO receives 93,010 RSUs, sells shares for tax

Rhea-AI Filing Summary

CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported equity compensation and a related share sale. On 01/23/2026 she received 93,010 shares of common stock for $0.00 per share as a grant of restricted stock units that convert into common stock.

The restricted stock units vest 1/4 at grant and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant date. On the same day, 10,778 shares of common stock were disposed of at $7.27 per share, typically reflecting shares withheld or sold to cover taxes, leaving her with 242,533 directly owned shares.

Insider Trade Summary

Net Buyer: 82,232 shares

Net Buy 2 txns

Insider Hurlburt Elizabeth

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	93,010	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	10,778	$7.27	$78K

Holdings After Transaction: Common Stock — 242,533 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM Learn about SEC filing dates

FAQ

What insider transactions did CorMedix (CRMD) report for the COO?

CorMedix reported that its COO, Elizabeth Hurlburt, received 93,010 shares of common stock from restricted stock units and disposed of 10,778 shares at $7.27 on January 23, 2026. After these transactions, she directly owned 242,533 CorMedix common shares.

How many CorMedix (CRMD) shares did the COO acquire and at what price?

The COO acquired 93,010 CorMedix common shares at a price of $0.00 per share on January 23, 2026. These shares came from restricted stock units that convert into common stock under her equity compensation arrangement and vest over several years.

Why were 10,778 CorMedix (CRMD) shares disposed of by the COO?

The Form 4 shows 10,778 CorMedix common shares disposed of at $7.27 per share on January 23, 2026, coded as “F.” Code F typically indicates shares withheld or sold to satisfy tax withholding obligations related to the restricted stock unit vesting.

What is the vesting schedule of the COO’s CorMedix (CRMD) restricted stock units?

The restricted stock units granted to the COO on January 23, 2026 vest over four tranches: one-quarter vests on the grant date, and, subject to continued employment, one-quarter vests on each of the first, second, and third anniversaries of the grant date.

How many CorMedix (CRMD) shares does the COO own after the reported transactions?

Following the reported January 23, 2026 transactions, the COO directly owned 242,533 CorMedix common shares. This reflects the 93,010-share grant of restricted stock units converted into stock, offset by the 10,778 shares disposed of to address tax obligations.

What does each CorMedix (CRMD) restricted stock unit granted to the COO represent?

Each restricted stock unit granted to the COO represents the right to receive one share of CorMedix common stock. These units convert into shares as they vest over time, subject to the COO’s continued employment with CorMedix according to the specified vesting schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurlburt Elizabeth

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		93,010	A	$0.00(1)	253,311	D
Common Stock	01/23/2026		F		10,778	D	$7.27	242,533	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.